Envista upgraded to Outperform from Neutral at Baird

Baird analyst Jeff Johnson upgraded Envista (NVST) to Outperform from Neutral with a price target of $23, up from $21. Baird’s May domestic dental survey notably improved following bad April findings, the analyst tells investors in a research note. The firm says its feedback consistently points to stable to slightly improved dental demand last couple months, including in the U.S., but not to extent of the sequential inflection seen in this month’s survey. It sees revenue and earnings upside for Envista in 2025 and 2026. Stable end markets and the recent China tariff relief will likely help this upside become increasingly apparent over the next couple quarters, contends Baird.